ERBB2 and breast carcinoma: The first human study with [64Cu]Cu-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) (64Cu)-trastuzumab was conducted by Tamura et al. in a cohort of six patients with primary or metastatic HER2-positive breast cancer [37].